In one paragraphArticle in Clinical and molecular hepatology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registryThe trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
3 · Its place in the literatureWho cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
4 · The recordCorrections and comments
5 · Who and what moneyAuthors and funding
2 authors.
Haiyu WangDepartment of Infectious Diseases, Nanfang Hospital, Southern Medical University, Guangzhou, China; State Key Laboratory of Multiorgan Injury Prevention and Treatment; Key Laboratory of Infectious Diseases Research in South China (Southern Medical University), Ministry of Education; Guangdong Provincial Key Laboratory for Prevention and Control of Major Liver Diseases; Guangdong Provincial Clinical Research Center for Viral Hepatitis; Guangdong Institute of Hepatology; Guangdong Provincial Research Center for Liver Fibrosis Engineering and Technology; Guangzhou, China.
Jinjun ChenDepartment of Infectious Diseases, Nanfang Hospital, Southern Medical University, Guangzhou, China; State Key Laboratory of Multiorgan Injury Prevention and Treatment; Key Laboratory of Infectious Diseases Research in South China (Southern Medical University), Ministry of Education; Guangdong Provincial Key Laboratory for Prevention and Control of Major Liver Diseases; Guangdong Provincial Clinical Research Center for Viral Hepatitis; Guangdong Institute of Hepatology; Guangdong Provincial Research Center for Liver Fibrosis Engineering and Technology; Guangzhou, China.
Funding
Clinical Research Program of Nanfang Hospital, Southern Medical University 2018CR037Clinical Research Program of Nanfang Hospital, Southern Medical University 2020CR026Clinical Research Start-up Program of Southern Medical University by High-level University Construction Funding of Guangdong Provincial Department of Education LC2019ZD006Key-Area Research and Development Program of Guangdong Province 2019B020227004Local Innovative and Research Teams Project of Guangdong Pearl River Talents Program 2017BT01S131National Key Research and Development Program of China 2022YFC2304800National Natural Science Foundation of China 82070650National Natural Science Foundation of China 82200674National Natural Science Foundation of China 82370614National Postdoctoral Program for Innovative Talents of China BX20220144National Science and Technology Major Project 2018ZX10723203Postdoctoral Science Foundation of China 2022M711518President Foundation of Nanfang Hospital, Southern Medical University 2019Z003
6 · The paper itselfAbstract
PubMed holds no abstract for this paper.
Indexed as
Baveno VI-SSMNon-selective beta-blocker therapyPortal hypertension
Identifiers
PMID40509578
PMCPMC13129735
What OpenQuestion holds
Textmetadata
LicenceCC BY-NC
Read underepoch 390